Targeting mesothelin receptors with drug-loaded bacterial nanocells suppresses human mesothelioma tumour growth in mouse xenograft models

• Mohamed A. Alfaleh,

  Roles Conceptualization, Investigation, Methodology, Project administration, Writing – original draft

  Affiliations Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, Queensland, Australia, Faculty of Pharmacy; King Abdulaziz University, Jeddah, Saudi Arabia

  ⨯
• Christopher B. Howard ,

  Roles Conceptualization, Investigation, Methodology, Project administration, Supervision, Writing – original draft, Writing – review & editing

  * E-mail: c.howard2@uq.edu.au

  Affiliations Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, Queensland, Australia, Centre for Advanced Imaging, The University of Queensland, Brisbane, Queensland, Australia, Australian Research Council Training Centre for Biopharmaceutical Innovation, The University of Queensland, Brisbane, Queensland, Australia

  http://orcid.org/0000-0001-9797-8686

  ⨯
• Ilya Sedliarou,

  Roles Conceptualization, Investigation, Methodology, Writing – review & editing

  Affiliation Cancer Therapeutics, EnGeneIC Ltd, Sydney, New South Wales, Australia

  ⨯
• Martina L. Jones,

  Roles Conceptualization, Methodology, Project administration, Supervision, Writing – review & editing

  Affiliations Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, Queensland, Australia, Australian Research Council Training Centre for Biopharmaceutical Innovation, The University of Queensland, Brisbane, Queensland, Australia

  ⨯
• Reema Gudhka,

  Roles Investigation

  Affiliation Cancer Therapeutics, EnGeneIC Ltd, Sydney, New South Wales, Australia

  ⨯
• Natasha Vanegas,

  Roles Investigation

  Affiliation Cancer Therapeutics, EnGeneIC Ltd, Sydney, New South Wales, Australia

  ⨯
• Jocelyn Weiss,

  Roles Investigation

  Affiliation Cancer Therapeutics, EnGeneIC Ltd, Sydney, New South Wales, Australia

  ⨯
• Julia H. Suurbach,

  Roles Investigation

  Affiliation Cancer Therapeutics, EnGeneIC Ltd, Sydney, New South Wales, Australia

  ⨯
• Christopher J. de Bakker,

  Roles Investigation, Methodology, Writing – review & editing

  Affiliation Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, Queensland, Australia

  ⨯
• Michael R. Milne,

  Roles Investigation

  Affiliation Queensland Brain Institute (QBI), The University of Queensland, Brisbane, Queensland, Australia

  ⨯
• Bree A. Rumballe,

  Roles Investigation

  Affiliation Queensland Brain Institute (QBI), The University of Queensland, Brisbane, Queensland, Australia

  ⨯
• Jennifer A. MacDiarmid,

  Roles Conceptualization

  Affiliation Cancer Therapeutics, EnGeneIC Ltd, Sydney, New South Wales, Australia

  ⨯
• Himanshu Brahmbhatt,

  Roles Conceptualization

  Affiliation Cancer Therapeutics, EnGeneIC Ltd, Sydney, New South Wales, Australia

  ⨯
• Stephen M. Mahler

  Roles Conceptualization, Funding acquisition, Project administration, Supervision, Writing – review & editing

  Affiliations Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, Queensland, Australia, Australian Research Council Training Centre for Biopharmaceutical Innovation, The University of Queensland, Brisbane, Queensland, Australia

  ⨯